{"generic":"Obinutuzumab","drugs":["Gazyva","Obinutuzumab"],"mono":{"0":{"id":"jy7vs0","title":"Generic Names","mono":"Obinutuzumab"},"1":{"id":"jy7vs1","title":"Dosing and Indications","sub":[{"id":"jy7vs1b4","title":"Adult Dosing","mono":"<ul><li>screen all patients for hepatitis B virus prior to initiation by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc)<\/li><li><b>Chronic lymphoid leukemia, Previously untreated, in combination with chlorambucil:<\/b> 28-day cycles: cycle 1, day 1, 100 mg IV at 25 mg\/hr over 4 hours (do not increase infusion rate); cycle 1, day 2, 900 mg IV at 50 mg\/hr (may increase by 50 mg\/hr every 30 minutes to maximum rate of 400 mg\/hr); cycle 1, day 8 and day 15, 1000 mg IV at a starting rate of 100 mg\/hr (may increase by 100 mg\/hr increments every 30 minutes to maximum rate of 400 mg\/hr); cycles 2 through 6, day 1, 1000 mg IV at a starting rate of 100 mg\/hr (may increase by 100 mg\/hr increments every 30 minutes to maximum rate of 400 mg\/hr); premedicate all patients with acetaminophen 650 to 1000 mg at least 30 minutes before infusion (all cycles), dexamethasone 20 mg IV or methylprednisolone 80 mg IV at least 1 hour before infusion (cycle 1, days 1 and 2), antihistamine (eg, diphenhydramine 50 mg) at least 30 minutes before infusion (cycle 1, days 1 and 2); premedicate patients with an infusion reaction of grade 1 or higher with a previous infusion with antihistamine (eg, diphenhydramine 50 mg) at least 30 minutes before infusion; premedicate patients with a grade 3 infusion reaction with a previous infusion or with a lymphocyte count of greater than 25 x 10(9)\/L before the next treatment with dexamethasone 20 mg IV or methylprednisolone 80 mg IV at least 1 hour before infusion; for patients with neutropenia, consider antimicrobial, antiviral, and antifungal premedication; for patients with high tumor burden or circulating absolute lymphocyte count greater than 25 x 10(9)\/L, premedicate with antihyperuricemics (eg, allopurinol) starting 12 to 24 hours before infusion and ensure adequate hydration; for patients on antihypertensive medications, consider withholding those medications for 12 hours before, during, and 1 hour after infusion<\/li><\/ul>"},{"id":"jy7vs1b5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"jy7vs1b6","title":"Dose Adjustments","mono":"<ul><li><b>hematologic toxicity:<\/b> interrupt therapy for grade 3 or 4 cytopenia<\/li><li><b>infection:<\/b> interrupt therapy if infection develops<\/li><li><b>infusion reaction, grade 4:<\/b> stop infusion and permanently discontinue therapy<\/li><li><b>infusion reaction, grade 3:<\/b> interrupt infusion and manage symptoms; resume at no more than half the rate after symptom resolution; permanently discontinue if grade 3 reaction occurs with rechallenge<\/li><li><b>infusion reaction, grade 1 or 2:<\/b> reduce infusion rate or interrupt infusion and manage symptoms; continue or resume infusion after symptom resolution; increase infusion rate at increments and intervals appropriate for treatment cycle dose if no further symptoms develop<\/li><li><b>nonhematologic toxicity:<\/b> interrupt therapy for a grade 2 or higher nonhematologic toxicity<\/li><\/ul>"},{"id":"jy7vs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Chronic lymphoid leukemia, Previously untreated, in combination with chlorambucil<br\/>"}]},"2":{"id":"jy7vs2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Hepatitis B virus (HBV) reactivation can occur in patients receiving obinutuzumab or other CD20-directed cytolytic antibodies, which can progress to life-threatening or fatal fulminant hepatitis or hepatic failure. Screen patients at baseline for HBV infection. Monitor HBV-positive patients during and after treatment with obinutuzumab. If HBV reactivation occurs, discontinue obinutuzumab and concomitant medications. Life-threatening or fatal progressive multifocal leukoencephalopathy has also been reported.<br\/>"},"3":{"id":"jy7vs3","title":"Contraindications\/Warnings","sub":[{"id":"jy7vs3b9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"jy7vs3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Hepatitis B virus reactivation may occur and can progress to life-threatening or fatal fulminant hepatitis or hepatic failure; baseline screening and monitoring during and after treatment recommended; discontinue if condition occurs<\/li><li>-- Life-threatening or fatal progressive multifocal leukoencephalopathy (PML) has been reported; consider PML diagnosis for new-onset or worsening neurological manifestations; discontinue use if PML occurs<\/li><li>Cardiovascular:<\/li><li>-- Hypotension may occur as part of an infusion reaction; consider interruption of antihypertensive treatment for 12 hours prior to and for 1 hour following each infusion; evaluate the risk versus benefit of withholding antihypertensive treatment for patients at risk for hypertensive crisis<\/li><li>-- Patients with preexisting cardiac and pulmonary conditions at increased risk for severe infusion reactions; frequent monitoring recommended during and after infusion<\/li><li>Hematologic:<\/li><li>-- Grade 3 or 4 neutropenia, including late-onset and long-term cases has been reported; monitoring and antiviral, antifungal, and antimicrobial prophylaxis is recommended in patients with preexisting neutropenia<\/li><li>-- Fatal hemorrhages have occurred during the first cycle of treatment; frequent monitoring recommended, especially during the first treatment cycle; treatment interruption or dose adjustments may be required<\/li><li>-- Grade 3 or 4 thrombocytopenia has been reported, including first-cycle onset; frequent monitoring recommended, especially during the first treatment cycle, and treatment interruption or dose adjustments may be required<\/li><li>Immunologic Effects:<\/li><li>-- Severe and life-threatening infusion reactions have been reported; premedication and monitoring recommended, treatment interruption or permanent discontinuation may be required<\/li><li>-- Severe bacterial, fungal, and new or reactivated viral infections, including fatal cases, have been reported, with an increased risk in patients with a recurring or chronic infection history; do not use in patients with an active infection<\/li><li>Other:<\/li><li>-- Tumor lysis syndrome, which may progress to electrolyte imbalances (ie, hyperkalemia, hypocalcemia, hyperphosphatemia), hyperuricemia, and acute renal failure, may occur within 12 to 24 hours following first infusion; premedication and hydration recommended prior to infusion<\/li><li>-- Patients with high tumor burden or high circulating lymphocyte count (greater than 25 x 10(9)\/L) at increased risk for tumor lysis syndrome; premedication and hydration recommended prior to infusion<\/li><li>Concomitant Use:<\/li><li>-- Immunization during treatment with live virus vaccines not recommended<\/li><\/ul>"},{"id":"jy7vs3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jy7vs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jy7vs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Hematologic:<\/b>Anemia, All grades (12%), Neutropenia, All grades (38% to 41%), Thrombocytopenia, All grades (14% to 15%)<\/li><li><b>Musculoskeletal:<\/b>Disorder of musculoskeletal system (18%)<\/li><li><b>Respiratory:<\/b>Cough (10%)<\/li><li><b>Other:<\/b>Fever (All grades, 9% to 10%; grade 3 or 4, less than 1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (5%), Hemorrhage, Fatal, Leukopenia, Grade 3 or 4 (4% to 5%), Neutropenia, Grade 3 or 4 (33% to 35%), Thrombocytopenia, Grade 3 or 4 (10% to 11%)<\/li><li><b>Neurologic:<\/b>Progressive multifocal leukoencephalopathy<\/li><li><b>Other:<\/b>Infusion reaction (All grades, 66% to 69%; grade 3 or 4, 20% to 21%), Tumor lysis syndrome (2%)<\/li><\/ul>"},"6":{"id":"jy7vs6","title":"Drug Name Info","sub":{"0":{"id":"jy7vs6b17","title":"US Trade Names","mono":"Gazyva<br\/>"},"2":{"id":"jy7vs6b19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"jy7vs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jy7vs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jy7vs7","title":"Mechanism Of Action","mono":"Obinutuzumab is a monoclonal antibody (IgG1 subclass) that targets the CD20 antigen on the surface of pre B- and mature B-lymphocytes and after binding causes B-cell lysis. B-cell depletion in peripheral blood is not directly correlated with depletion in solid organs or in malignant deposits and has not been shown to directly correlate to clinical response. It has been shown that obinutuzumab activates polymorphoneclear neutrophils (PMNs), produces radical oxygen, and mediates phagocytosis by binding to CD16A and CD16B NA1 and NA2 isoforms.<br\/>"},"8":{"id":"jy7vs8","title":"Pharmacokinetics","sub":{"1":{"id":"jy7vs8b24","title":"Distribution","mono":"Vd: 3.9 L <br\/>"},"3":{"id":"jy7vs8b26","title":"Excretion","mono":"Total body: 0.09 L\/day <br\/>"},"4":{"id":"jy7vs8b27","title":"Elimination Half Life","mono":"29.7 days <br\/>"}}},"9":{"id":"jy7vs9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>to prepare cycle 1, day 1 and 2 solution, dilute 100 mg in 100 mL NS for immediate infusion on day 1; dilute 900 mg in 250 mL NS and refrigerate; use after coming to room temperature on day 2<\/li><li>to prepare 1000-mg doses, dilute 1000 mg in 250 mL NS infusion bag<\/li><li>dilute into NS infusion bag to final concentration of 0.4 to 4 mg\/mL; do not use other diluents (eg, D5W)<\/li><li>to mix diluted solution, invert gently (do not shake); may store at 2 to 8 degrees C (36 to 46 degrees F) for up to 24 hours (do not freeze)<\/li><li>administer by IV infusion only; do not administer IV push or IV bolus<\/li><li>do not mix with other drugs<\/li><\/ul>"},"10":{"id":"jy7vs10","title":"Monitoring","mono":"<ul><li>Evidence of tumor response indicates efficacy<\/li><li>Hepatitis B infection; prior to initiating therapy<\/li><li>Liver function; during treatment, especially the first cycle<\/li><li>Laboratory and clinical signs of active HBV infection, in patients with current or prior HBV infection; throughout therapy and for several months following discontinuation of therapy<\/li><li>Blood counts; regularly; include differential<\/li><li>Infusion reactions; during the entire infusion; more frequent monitoring during infusion and post-infusion period for patients with pre-existing cardiac or pulmonary conditions<\/li><li>Signs or symptoms of developing infection; particularly in neutropenic patients<\/li><li>Signs and symptoms of thrombocytopenia or hemorrhagic events; frequently and especially during the first treatment cycle.<\/li><\/ul>"},"11":{"id":"jy7vs11","title":"How Supplied","mono":"<b>Gazyva<\/b><br\/>Intravenous Solution: 25 MG\/ML<br\/>"},"13":{"id":"jy7vs13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of a late-onset infusion reaction.<\/li><li>Instruct patient to report symptoms of infection or bleeding.<\/li><li>Tell patient to report symptoms of tumor lysis syndrome or hepatitis.<\/li><li>Side effects may include anemia, cough, pyrexia, and musculoskeletal pain.<\/li><li>Warn patient to report symptoms of progressive multifocal leukoencephalopathy (neurologic symptoms).<\/li><li>Advise patient to avoid live viral vaccines during therapy.<\/li><\/ul>"}}}